Whitlock J A, Greer J P, Lukens J N
Vanderbilt University Medical Center, Division of Pediatric Hematology-Oncology, Nashville, TN 37232.
Cancer. 1991 Aug 1;68(3):600-4. doi: 10.1002/1097-0142(19910801)68:3<600::aid-cncr2820680326>3.0.co;2-f.
Thirty-seven children and adults who developed acute nonlymphocytic leukemia after the administration of chemotherapy that included etoposide or teniposide for a variety of hematologic and solid malignancies were identified. The secondary leukemia that occurred in these patients could be distinguished from the secondary leukemia that occurs after treatment with alkylating agents by the following: a shorter latency period; a predominance of monocytic or myelomonocytic features; and frequent cytogenetic abnormalities involving 11q23. Patients receiving an epipodophyllotoxin are at risk for developing secondary leukemia that has features distinct from the syndrome of secondary leukemia associated with alkylating agents.
我们确定了37名儿童和成人，他们在接受包括依托泊苷或替尼泊苷在内的化疗以治疗各种血液系统和实体恶性肿瘤后发生了急性非淋巴细胞白血病。这些患者发生的继发性白血病可通过以下方面与烷化剂治疗后发生的继发性白血病相区分：潜伏期较短；单核细胞或粒单核细胞特征占优势；以及频繁出现涉及11q23的细胞遗传学异常。接受表鬼臼毒素治疗的患者有发生继发性白血病的风险，其特征与烷化剂相关的继发性白血病综合征不同。
